Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bendroflumethiazide + amiloride
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of bendroflumethiazide, a thiazide diuretic, and amiloride, a potassium-sparing diuretic. This combination is used to treat hypertension while preventing excessive potassium loss that can occur with thiazide diuretics alone. Both components work on the kidneys - bendroflumethiazide increases urine output and reduces blood pressure, while amiloride prevents potassium excretion.
02
Targets
ENaCSLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)
Beyond the preview
Go deeper on bendroflumethiazide + amiloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bendroflumethiazide + amiloride.